Form4insider filings, from the source

SEC Form 4 · accession 0001645627-17-000098

ENDONOVO THERAPEUTICS, INC. · ENDV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael Scott Mann
Officer — President · 10% Owner
Period of report
Jul 20, 2017
Accepted (ET)
Jul 24, 2017 · 3:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJul 20, 2017P2,000$0.0219A21,876,389D
Common StockJul 20, 2017P2,000$0.0219A21,878,389D
Common StockJul 20, 2017P5,000$0.0219A21,883,389D
Common StockJul 20, 2017P2,000$0.0212A21,885,389D
Common StockJul 20, 2017P2,000$0.0218A21,887,389D
Common StockJul 20, 2017P5,000$0.0195A21,892,389D
Common StockJul 20, 2017P5,000$0.0195A21,897,389D
Common StockJul 20, 2017P5,000$0.0195A21,902,389D
Common StockJul 20, 2017P5,000$0.0183A21,907,389D
Common StockJul 20, 2017P2,000$0.0183A21,909,389D
Common StockJul 20, 2017P2,000$0.0182A21,911,389D
Common StockJul 20, 2017P2,000$0.0182A21,913,389D
Common StockJul 20, 2017P2,000$0.0182A21,915,389D
Common StockJul 20, 2017P2,000$0.02A21,917,389D
Common StockJul 20, 2017P5,000$0.0191A21,922,389D
Common StockJul 20, 2017P2,000$0.0194A21,924,389D
Common StockJul 20, 2017P2,000$0.0195A21,926,389D
Common StockJul 20, 2017P10,000$0.0195A21,936,389D
Common StockJul 20, 2017P2,000$0.02A21,938,389D
Common StockJul 20, 2017P5,000$0.0216A21,943,389D
Common StockJul 20, 2017P2,000$0.0213A21,945,389D
Common StockJul 20, 2017P2,000$0.0214A21,947,389D
Common StockJul 20, 2017P2,000$0.0216A21,949,389D
Common StockJul 20, 2017P2,000$0.0215A21,951,389D
Common StockJul 20, 2017P5,000$0.0215A21,956,389D
Common StockJul 20, 2017P2,000$0.0216A21,958,389D
Common StockJul 20, 2017P2,000$0.0216A21,960,389D
Common StockJul 20, 2017P2,000$0.0216A21,962,389D
Common StockJul 21, 2017P2,000$0.0214A21,964,389D
Common StockJul 21, 2017P2,000$0.0214A21,966,389D

Table II — derivative securities

No Table II lines on this filing.